Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | July 2006 |
| End Date: | June 2020 |
Phase II Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment
during lymphocyte recovery.
during lymphocyte recovery.
Inclusion Criteria:
- Confirmed hematopathology diagnosis of AML receiving marrow suppressive treatment
- Total WBC recovery of 500 mm3 prior to IL-2 treatment
- Platelet count of at least 20,000 mm3 prior to starting IL-2 treatment
- Active infection controlled prior to starting IL-2 treatment
- Stable systolic blood pressure > 90mm Hg prior to starting IL-2 treatment
- O2 saturation >90% prior to starting treatment
- Stable cardiopulmonary status prior to starting IL-2 treatment
- Serum creatinine < or equal to 2.0 mg/dl
- Total bilirubin and AST <3x upper limits normal
Exclusion Criteria:
- Acute Promyelocytic Leukemia
- Active thrombocytopenic bleeding
- Cardiac ejection fraction below 45%
- Pregnancy and/or lactation
We found this trial at
1
site
Click here to add this to my saved trials
